TradeFlare's AI research teams analysed IFRX on 3 market nights between June 4, 2026 and September 18, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 18, 2026 | HOLD | $2.06 | $2.47 / $1.75 | -9.6% | not yet | The stock is in a neutral technical state with a high risk score, suggesting a need for more clarity before initiating a position. |
| June 5, 2026 | BUY | $2.00 | — / — | -13.0% | +15.2% | Promising clinical data for IFRX's lead drug candidates. |
| June 4, 2026 | BUY | $2.06 | — / — | -16.0% | +5.5% | The current market regime and the stock's technical and risk profile do not support a buy decision. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.